S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.79 (-1.67%)
AAPL   172.97 (-0.68%)
MSFT   286.89 (-1.13%)
META   168.20 (-3.70%)
GOOGL   117.70 (-2.06%)
AMZN   138.73 (-2.51%)
TSLA   887.33 (-2.34%)
NVDA   179.68 (-4.29%)
NIO   19.06 (-4.27%)
BABA   89.39 (-1.49%)
AMD   95.79 (-4.63%)
T   18.39 (-0.22%)
MU   60.91 (-3.29%)
CGC   3.84 (+0.79%)
F   15.86 (-1.80%)
GE   77.61 (-2.02%)
DIS   120.41 (-1.84%)
AMC   18.20 (-5.65%)
PYPL   97.44 (-2.42%)
PFE   49.36 (+1.61%)
NFLX   238.63 (-2.67%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.79 (-1.67%)
AAPL   172.97 (-0.68%)
MSFT   286.89 (-1.13%)
META   168.20 (-3.70%)
GOOGL   117.70 (-2.06%)
AMZN   138.73 (-2.51%)
TSLA   887.33 (-2.34%)
NVDA   179.68 (-4.29%)
NIO   19.06 (-4.27%)
BABA   89.39 (-1.49%)
AMD   95.79 (-4.63%)
T   18.39 (-0.22%)
MU   60.91 (-3.29%)
CGC   3.84 (+0.79%)
F   15.86 (-1.80%)
GE   77.61 (-2.02%)
DIS   120.41 (-1.84%)
AMC   18.20 (-5.65%)
PYPL   97.44 (-2.42%)
PFE   49.36 (+1.61%)
NFLX   238.63 (-2.67%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.79 (-1.67%)
AAPL   172.97 (-0.68%)
MSFT   286.89 (-1.13%)
META   168.20 (-3.70%)
GOOGL   117.70 (-2.06%)
AMZN   138.73 (-2.51%)
TSLA   887.33 (-2.34%)
NVDA   179.68 (-4.29%)
NIO   19.06 (-4.27%)
BABA   89.39 (-1.49%)
AMD   95.79 (-4.63%)
T   18.39 (-0.22%)
MU   60.91 (-3.29%)
CGC   3.84 (+0.79%)
F   15.86 (-1.80%)
GE   77.61 (-2.02%)
DIS   120.41 (-1.84%)
AMC   18.20 (-5.65%)
PYPL   97.44 (-2.42%)
PFE   49.36 (+1.61%)
NFLX   238.63 (-2.67%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.79 (-1.67%)
AAPL   172.97 (-0.68%)
MSFT   286.89 (-1.13%)
META   168.20 (-3.70%)
GOOGL   117.70 (-2.06%)
AMZN   138.73 (-2.51%)
TSLA   887.33 (-2.34%)
NVDA   179.68 (-4.29%)
NIO   19.06 (-4.27%)
BABA   89.39 (-1.49%)
AMD   95.79 (-4.63%)
T   18.39 (-0.22%)
MU   60.91 (-3.29%)
CGC   3.84 (+0.79%)
F   15.86 (-1.80%)
GE   77.61 (-2.02%)
DIS   120.41 (-1.84%)
AMC   18.20 (-5.65%)
PYPL   97.44 (-2.42%)
PFE   49.36 (+1.61%)
NFLX   238.63 (-2.67%)
Followed 208 Times  
NYSE:PFE

Pfizer - PFE Stock Forecast, Price & News

$49.36
+0.78 (+1.61%)
(As of 08/19/2022 01:04 PM ET)
Add
Compare
Today's Range
$48.38
▼
$49.40
50-Day Range
$46.53
▼
$53.42
52-Week Range
$40.94
▼
$61.71
Volume
486,836 shs
Average Volume
19.20 million shs
Market Capitalization
$277.03 billion
P/E Ratio
9.66
Dividend Yield
3.25%
Price Target
$57.50

Pfizer MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
17.3% Upside
$57.50 Price Target
Short Interest
Healthy
1.07% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.67
Upright™ Environmental Score
News Sentiment
0.33mentions of Pfizer in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$227,603 Sold Last Quarter
Proj. Earnings Growth
-17.58%
From $6.54 to $5.39 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.01 out of 5 stars

Medical Sector

29th out of 1,119 stocks

Pharmaceutical Preparations Industry

7th out of 549 stocks

See Top Rated MarketRank™ Stocks Here
PFE stock logo

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Barclays upped their target price on shares of Pfizer to $52.00 in a research report on Tuesday, August 9th. The Goldman Sachs Group set a $50.00 target price on shares of Pfizer in a research note on Friday, July 29th. Morgan Stanley lowered their price objective on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating for the company in a research report on Friday, July 8th. Berenberg Bank set a $50.00 price objective on shares of Pfizer in a research report on Friday, May 27th. Finally, JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a report on Tuesday, June 28th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $57.50.

Pfizer Stock Down 1.4 %

PFE opened at $48.58 on Friday. Pfizer has a 1-year low of $40.94 and a 1-year high of $61.71. The firm's 50 day simple moving average is $50.44 and its two-hundred day simple moving average is $50.88. The company has a market capitalization of $272.65 billion, a PE ratio of 9.51, a PEG ratio of 0.61 and a beta of 0.67. The company has a current ratio of 1.42, a quick ratio of 1.20 and a debt-to-equity ratio of 0.39.

Pfizer (NYSE:PFE - Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. Pfizer's revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.07 EPS. As a group, equities analysts forecast that Pfizer will post 6.54 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.29%. The ex-dividend date is Thursday, July 28th. Pfizer's payout ratio is 31.31%.

Insider Activity at Pfizer

In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the firm's stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the sale, the senior vice president now owns 10,846 shares of the company's stock, valued at $585,250.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by corporate insiders.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

August 9, 2022 | marketbeat.com
Are Medtronic And Intuitive Surgical Poised For Big Growth? (PFE)
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
August 3, 2022 | marketbeat.com
3 Pharma Stocks' Post-Earnings Price Moves (PFE)
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
August 2, 2022 | marketbeat.com
3 Health Care Stocks in Great Financial Health (PFE)
Health care’s potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.
August 18, 2022 | marketwatch.com
Pfizer Inc. stock underperforms Thursday when compared to competitors - MarketWatch
August 17, 2022 | forbes.com
Teens’ Protection From Pfizer’s Covid Shot Fades Weeks After Vaccination—But Shot Still Wards Off Serious Illness, Study Finds - Forbes
August 17, 2022 | benzinga.com
Icannex Taps Ex Pfizer, FDA & Regulatory Affairs Expert - Benzinga
August 17, 2022 | americanbankingnews.com
Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 16, 2022 | reuters.com
Pfizer CEO Bourla shows mild symptoms after testing positive for COVID
August 15, 2022 | cnn.com
Pfizer CEO Albert Bourla tests positive for Covid-19 and is experiencing 'very mild symptoms' - CNN
August 13, 2022 | nasdaq.com
Pfizer: Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine Posts Positive Results In Infants
August 13, 2022 | msn.com
Pfizer Stock Slumps Amid Litigation Concerns Linked to Zantac Heartburn Drug
August 13, 2022 | seekingalpha.com
Pfizer pneumococcal vaccine for children meets main goals in late-stage trial
August 12, 2022 | finance.yahoo.com
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
August 11, 2022 | fool.com
Why Pfizer Stock Slipped Today - The Motley Fool
August 11, 2022 | finance.yahoo.com
Why Pfizer Stock Slipped Today
August 11, 2022 | americanbankingnews.com
Pfizer (NYSE:PFE) PT Raised to $52.00
August 10, 2022 | bizjournals.com
Pfizer expands Chesterfield space to nearly 400,000 square feet - St. Louis Business Journal - The Business Journals
August 9, 2022 | marketwatch.com
: Get ready for more merger mania in pharma sector the rest of the year
August 9, 2022 | finance.yahoo.com
ClearBridge All Cap Value Strategy Added Pfizer Inc. (PFE) in its Portfolio
August 9, 2022 | washingtonpost.com
Pfizer and Valneva developing new Lyme disease vaccine - The Washington Post
August 8, 2022 | ft.com
BioNTech and Pfizer to begin clinical trial of vaccine for new Covid variants - Financial Times
August 8, 2022 | finance.yahoo.com
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
August 8, 2022 | marketwatch.com
Pfizer strikes $5.4 billion deal for Global Blood Therapeutics
August 8, 2022 | seekingalpha.com
Valneva Stock: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love (NASDAQ:VALN) - Seeking Alpha
August 5, 2022 | seekingalpha.com
Pfizer Looks Oversold (NYSE:PFE) - Seeking Alpha
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Company Calendar

Ex-Dividend for 6/10 Dividend
5/12/2022
Dividend Payable
6/10/2022
Last Earnings
7/28/2022
Ex-Dividend for 9/6 Dividend
7/28/2022
Today
8/19/2022
Dividend Payable
9/06/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:PFE
CUSIP
71708110
CIK
78003
Web
www.pfizer.com
Phone
(212) 733-2323
Fax
302-655-5049
Employees
79,000
Year Founded
1849

Price Target and Rating

Average Stock Price Forecast
$57.50
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+16.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
18 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.11
Trailing P/E Ratio
9.66
Forward P/E Ratio
7.55
P/E Growth
0.6
Net Income
$21.98 billion
Net Margins
28.92%
Pretax Margin
31.74%
Return on Equity
43.18%
Return on Assets
18.89%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
1.42
Quick Ratio
1.20

Sales & Book Value

Annual Sales
$81.29 billion
Price / Sales
3.41
Cash Flow
$5.43 per share
Price / Cash Flow
9.09
Book Value
$15.59 per share
Price / Book
3.17

Miscellaneous

Outstanding Shares
5,612,350,000
Free Float
5,609,546,000
Market Cap
$277.03 billion
Optionable
Optionable
Beta
0.67

Social Links


Key Executives

  • Dr. Albert Bourla D.V.M.Dr. Albert Bourla D.V.M. (Age 60)
    DVM, Ph.D., Chairman & CEO
    Comp: $11.07M
  • Mr. Frank A. D'Amelio (Age 64)
    CFO & Exec. VP
    Comp: $5.14M
  • Dr. Mikael Dolsten M.D. (Age 64)
    Ph.D., Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
    Comp: $5.36M
  • Mr. Douglas M. LanklerMr. Douglas M. Lankler (Age 56)
    Exec. VP & Gen. Counsel
    Comp: $3.78M
  • Mr. John D. YoungMr. John D. Young (Age 57)
    Advisor
    Comp: $4.25M
  • Ms. Angela Hwang (Age 56)
    Group Pres of Biopharmaceuticals Group
    Comp: $4.79M
  • Mr. David M. Denton (Age 57)
    Chief Financial Officer & Exec. VP
  • Ms. Jennifer B. DamicoMs. Jennifer B. Damico (Age 54)
    Sr. VP, Controller & Principal Accounting Officer
  • Ms. Lidia L. Fonseca (Age 53)
    Exec. VP and Chief Digital & Technology Officer
  • Mr. Christopher J. Stevo CFA
    Sr. VP & Chief Investor Relations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PFE Stock - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 9 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PFE shares.
View PFE analyst ratings or view top-rated stocks.

What is Pfizer's stock price forecast for 2022?

18 Wall Street analysts have issued 12-month price targets for Pfizer's shares. Their PFE share price forecasts range from $45.00 to $76.00. On average, they anticipate the company's share price to reach $57.50 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for PFE or view top-rated stocks among Wall Street analysts.

How have PFE shares performed in 2022?

Pfizer's stock was trading at $59.05 at the beginning of 2022. Since then, PFE stock has decreased by 17.7% and is now trading at $48.58.
View the best growth stocks for 2022 here.

When is Pfizer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PFE earnings forecast.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) posted its quarterly earnings data on Thursday, July, 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. The biopharmaceutical company earned $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a trailing twelve-month return on equity of 43.18%. Pfizer's revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.07 earnings per share.
Read the conference call transcript.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, June 23rd. Stockholders of record on Wednesday, June 29th will be paid a dividend of $0.40 per share on Tuesday, September 6th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date is Thursday, July 28th.
Read our dividend analysis for PFE.

Is Pfizer a good dividend stock?

Pfizer (NYSE:PFE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 3.25%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PFE will have a dividend payout ratio of 29.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $6.30-$6.45 for the period, compared to the consensus estimate of $6.62. The company issued revenue guidance of $98.00 billion-$102.00 billion, compared to the consensus revenue estimate of $102.92 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (5.12%), Northern Trust Corp (1.19%), Massachusetts Financial Services Co. MA (0.75%), Price T Rowe Associates Inc. MD (0.62%), UBS Asset Management Americas Inc. (0.46%) and Swiss National Bank (0.43%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Ronald E Blaylock, Scott Gottlieb and William R Carapezzi Jr.
View institutional ownership trends.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $48.58.

How much money does Pfizer make?

Pfizer (NYSE:PFE) has a market capitalization of $272.65 billion and generates $81.29 billion in revenue each year. The biopharmaceutical company earns $21.98 billion in net income (profit) each year or $5.11 on an earnings per share basis.

How many employees does Pfizer have?

The company employs 79,000 workers across the globe.

Does Pfizer have any subsidiaries?
The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Holdings B.V., AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alacer, Alpharma Holdings LLC, Alpharma Pharmaceuticals LLC, Alpharma Specialty Pharma LLC, Alpharma USHP LLC, American Food Industries LLC, Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Array BioPharma, Ayerst-Wyeth Pharmaceuticals LLC, BIND Therapeutics Inc., BINESA 2002 S.L., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Bioren LLC, Blue Whale Re Ltd., C.E. Commercial Holdings C.V., C.E. Commercial Investments C.V., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Continental Pharma Inc., Covx, Covx Technologies Ireland Limited, Cyanamid Inter-American Corporation, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion LUV Development Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Excaliard Pharmaceuticals Inc., Farminova Produtos Farmaceuticos de Inovacao Lda., Farmogene Productos Farmaceuticos Lda, Ferrosan A/S, Ferrosan International A/S, Ferrosan S.R.L., FoldRx Pharmaceuticals Inc., Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, G. D. Searle LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Greenstone LLC, Haptogen Limited, Hospira, Hospira (China) Enterprise Management Co. Ltd., Hospira Adelaide Pty Ltd, Hospira Aseptic Services Limited, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Chile Limitada, Hospira Deutschland GmbH, Hospira Enterprises B.V., Hospira France SAS, Hospira Healthcare B.V., Hospira Healthcare Corporation, Hospira Healthcare India Private Limited, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Invicta S.A., Hospira Ireland Holdings Unlimited Company, Hospira Ireland Sales Limited, Hospira Japan G.K., Hospira Limited, Hospira Malaysia Sdn Bhd, Hospira NZ Limited, Hospira Nordic AB, Hospira Philippines Inc., Hospira Portugal LDA, Hospira Produtos Hospitalares Ltda., Hospira Pte. Ltd., Hospira Pty Limited, Hospira Puerto Rico LLC, Hospira Singapore Pte Ltd, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, Industrial Santa Agape S.A., InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, JMI-Daniels Pharmaceuticals Inc., John Wyeth & Brother Limited, Kiinteistö oy Espoon Pellavaniementie 14, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Korea Pharma Holding Company Limited, Laboratoires Pfizer S.A., Laboratorios Parke Davis S.L., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Meridian Medical Technologies Inc., Meridian Medical Technologies Limited, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, NextWave Pharmaceuticals Incorporated, P-D Co. LLC, PAH USA IN8 LLC, PF Americas Holding C.V., PF Asia Manufacturing B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings S.a.r.l., PF Prism S.á.r.l., PFE Holdings G.K., PFE PHAC Holdings 1 LLC, PFE Pfizer Holdings 1 LLC, PFE Wyeth Holdings LLC, PFE Wyeth-Ayerst (Asia) LLC, PHILCO Holdings S.à r.l., PHIVCO Corp., PHIVCO Holdco S.à r.l., PHIVCO Luxembourg S.à r.l., PN Mexico LLC, PT. Pfizer Parke Davis, Parke Davis & Company LLC, Parke Davis Limited, Parke Davis Productos Farmaceuticos Lda, Parke-Davis Manufacturing Corp., Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Limited, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Africa & Middle East for Pharmaceuticals Veterinarian Products & Chemicals S.A.E., Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Asia Pacific Pte Ltd., Pfizer Atlantic Holdings S.a.r.l., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty. Ltd., Pfizer Australia Pty Limited, Pfizer B.V., Pfizer BH D.o.o., Pfizer Baltic Holdings B.V., Pfizer Biofarmacêutica Sociedade Unipessoal Lda, Pfizer Biologics (Hangzhou) Co. Ltd, Pfizer Biologics Ireland Holdings Limited, Pfizer Biotech Corporation, Pfizer Bolivia S.A., Pfizer Canada Inc., Pfizer CentreSource Asia Pacific Pte. Ltd., Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Commercial Holdings Coöperatief U.A., Pfizer Commercial Holdings TRAE Kft., Pfizer Commercial TRAE Trading Kft., Pfizer Consumer Healthcare AB, Pfizer Consumer Healthcare GmbH, Pfizer Consumer Healthcare Ltd., Pfizer Consumer Manufacturing Italy S.r.l., Pfizer Corporation, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer Domestic Ventures Limited, Pfizer Dominicana S.R.L, Pfizer ESP Pty Ltd, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Egypt S.A.E., Pfizer Enterprise Holdings B.V., Pfizer Enterprises LLC, Pfizer Enterprises SARL, Pfizer Europe Finance B.V., Pfizer Export B.V., Pfizer Export Company, Pfizer Export Holding Company B.V, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer Financial Services N.V./S.A., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer GEP S.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Group Luxembourg Sarl, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer HK Service Company Limited, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holding Ventures, Pfizer Holdings Corporation, Pfizer Holdings Europe Unlimited Company, Pfizer Holdings G.K., Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Holdings North America SARL, Pfizer Hungary Holdings TRAE Kft., Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer Innovative Supply Point International BVBA, Pfizer International LLC, Pfizer International Markets Coöperatief U.A., Pfizer International Operations, Pfizer International S. de R.L., Pfizer International Trading (Shanghai) Limited, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Investment Holdings S.a.r.l., Pfizer Ireland Investments Limited, Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Italy Group Holding S.r.l., Pfizer Japan Inc., Pfizer LLC, Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Laboratories PFE (Pty) Ltd, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limitada, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medical Technology Group (Belgium) N.V., Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Luxco SARL, Pfizer Mexico S.A. de C.V., Pfizer Middle East for Pharmaceuticals Animal Health and Chemicals S.A.E., Pfizer New Zealand Limited, Pfizer Norge AS, Pfizer North American Holdings Inc., Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE ApS, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE Australia Holding B.V., Pfizer PFE Australia Pty Ltd, Pfizer PFE B.V., Pfizer PFE Baltic Holdings B.V., Pfizer PFE Belgium SPRL, Pfizer PFE Brazil Holding S.à r.l., Pfizer PFE CIA. Ltda., Pfizer PFE Chile Holding LLC, Pfizer PFE Colombia Holding Corp., Pfizer PFE Colombia S.A.S, Pfizer PFE Commercial Holdings LLC, Pfizer PFE Croatia Holding B.V., Pfizer PFE Eastern Investments B.V., Pfizer PFE Finland Oy, Pfizer PFE France, Pfizer PFE Global Holdings B.V., Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V., Pfizer PFE Italy Holdco 2 S.à r.l., Pfizer PFE Italy Holdco S.à r.l., Pfizer PFE Korlátolt Felelősségű Társaság, Pfizer PFE Limited, Pfizer PFE Luxembourg S.à r.l., Pfizer PFE Mexico Holding 3 LLC, Pfizer PFE Netherlands Holding 1 C.V., Pfizer PFE New Zealand, Pfizer PFE New Zealand Holding B.V., Pfizer PFE Norway Holding S.à r.l., Pfizer PFE PILSA Holdco S.à r.l., Pfizer PFE Peru Holding LLC, Pfizer PFE Peru S.R.L., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Private Limited, Pfizer PFE S.R.L, Pfizer PFE Service Company Holding Coöperatief U.A., Pfizer PFE Singapore Holding B.V., Pfizer PFE Singapore Pte. Ltd., Pfizer PFE Spain B.V., Pfizer PFE Spain Holding S.L., Pfizer PFE Sweden Holding 2 S.á.r.l., Pfizer PFE Sweden Holding S.á.r.l., Pfizer PFE Switzerland GmbH, Pfizer PFE Turkey Holding 1 B.V., Pfizer PFE Turkey Holding 2 B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE US Holdings 1 LLC, Pfizer PFE US Holdings 2 LLC, Pfizer PFE US Holdings 3 LLC, Pfizer PFE US Holdings 4 LLC, Pfizer PFE US Holdings 5 LLC, Pfizer PFE spol. s r.o., Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Parke Davis (Thailand) Ltd., Pfizer Parke Davis Inc., Pfizer Parke Davis Sdn. Bhd., Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals B.V., Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals LLC, Pfizer Pharmaceuticals Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. (Belgium), Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SRB d.o.o., Pfizer Saidal Manufacturing, Pfizer Santé Familiale, Pfizer Saudi Limited, Pfizer Seiyaku K.K., Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Services 1, Pfizer Services LLC, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Singapore Trading Pte. Ltd., Pfizer Spain Holdings Coöperatief U.A., Pfizer Specialties Limited, Pfizer Strategic Investment Holdings LLC, Pfizer Sweden Partnership KB, Pfizer TRAE Holdings Kft., Pfizer Trading Polska sp.z.o.o., Pfizer Transactions Ireland Unlimited Company, Pfizer Transactions LLC, Pfizer Transactions Luxembourg SARL, Pfizer Transport LLC, Pfizer Ukraine LLC, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Venture Investments LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company Inc., Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia & Upjohn S.A. de C.V., Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Holding AB, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, Pharmacia Nostrum S.A., Pharmacia South Africa (Pty) Ltd, PowderJect Research Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig Produtos Farmaceuticos Lda., Roerig S.A., Sao Cristovao Participacoes Ltda., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Site Realty Inc., Solinor LLC, Sugen LLC, Tabor LLC, The Pfizer Incubator LLC, Therachon, Thiakis Limited, Treerly Health Co. Ltd, US Oral Pharmaceuticals Pty Ltd, Upjohn Laboratorios Lda., Vesterålens Naturprodukter A/S, Vesterålens Naturprodukter AB, Vesterålens Naturprodukter AS, Vesterålens Naturprodukter OY, Vicuron Holdings LLC, Vinci Farma S.A., W-L LLC, Warner Lambert, Warner Lambert Ilac Sanayi ve Ticaret Limited Sirketi, Warner Lambert del Uruguay S.A., Warner-Lambert (Thailand) Limited, Warner-Lambert Company AG, Warner-Lambert Company LLC, Warner-Lambert Guatemala Sociedad Anonima, Warner-Lambert S.A., Whitehall International Inc., Whitehall Laboratories Inc., Wyeth (Thailand) Ltd., Wyeth AB, Wyeth Australia Pty. Limited, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Canada ULC, Wyeth Consumer Healthcare LLC, Wyeth Europa Limited, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth KFT., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Lederle Vaccines S.A., Wyeth Pakistan Limited, Wyeth Pharmaceutical Co. Ltd., Wyeth Pharmaceuticals Company, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Pharmaceuticals Limited, Wyeth Puerto Rico Inc., Wyeth S.A.S, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth Whitehall SARL, Wyeth-Ayerst (Asia) Limited, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
When was Pfizer founded?

Pfizer was founded in 1849.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The official website for the company is www.pfizer.com. The biopharmaceutical company can be reached via phone at (212) 733-2323 or via fax at 302-655-5049.

This page (NYSE:PFE) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.